Comparative nephrotoxicity of cisplatin and new octahedral Pt(IV) complexes

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 2, 2007, Pages 237-243

  Kim, Won Kyu ^a   Kwon, Young Ee ^b  

^a Hanyang University   (South Korea)

^b Woosuk University   (South Korea)

Author keywords

Acid phophatase activity; Cisplatin; K101; K102; Nephrotoxicity; Octahedral Pt(IV) complex; Ultrastructure

Indexed keywords

ACETIC ACID DERIVATIVE; ACID PHOSPHATASE; CISPLATIN; CREATININE; K 101; K 102; PLATINUM COMPLEX; UNCLASSIFIED DRUG; URIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; ENZYME HISTOCHEMISTRY; FEMALE; IN VIVO STUDY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; LD 50; LIPOPHILICITY; MALE; MORPHOLOGY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL;

ACID PHOSPHATASE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; DESMOSOMES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INJECTIONS, INTRAPERITONEAL; KIDNEY DISEASES; KIDNEY TUBULES, PROXIMAL; LETHAL DOSE 50; MALE; MICE; MICE, INBRED ICR; MICROSCOPY, ELECTRON, TRANSMISSION; ORGANOPLATINUM COMPOUNDS;

EID: 34248341435     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0366-7     Document Type: Article

References (28)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (2969) Platinum compounds: a new class of potent antitumor agents. Nature 222:385-390
2. Crul M, van Waardenburg RC, Beijnen JH, Schellens JH (2002) DNA-based drug interactions of cisplatin. Cancer Treat Rev 28:291-303
3. Cosaert J, Quoix E (2000) Platinum drugs in the treatment of non-small-cell lung cancer. Br J Cancer 87:825-833
4. de Mulder PH (1999) The chemotherapy of head and neck cancer. Anticancer Drugs 10:S33-S37
5. Von Hoff DD, Schilsky R, Reichert CM, Reddick RL, Rozencweig M, Young RC, et al (1979) Toxic effects of cis-diaminedichloroplatinum(II) in man. Cancer Treat Rep 63:1527-1531
6. Krakoff IH (1979) Nephrotoxicity of cis- diaminedichloroplatinum(II). Cancer Treat Rep 63:1523-1525
7. Meyer KB, Madias NE (1994) Cisplatin nephrotoxicity. Miner Electrolyte Metab 20:201-213
8. Daugaard G, Abildgaard U (1989) Cisplatin nephrotoxicity. Cancer Chemother Pharmacol 25:1-9
9. Martinez F, Deray G, Dubois M, Beaufils H, Jacquiaud C, Bourbouze R, et al (1993) Comparative nephrotoxicity of carboplatin and cisplatin in euvolemic and dehydrated rats. Anticancer Drugs 4:85-90
10. Dobyan DC, Levi J, Jacobs C, Kosek J, Weiner MW (1980) Mechanism of cis-platinum nephrotoxicity. II. Morphologic observations. J Pharmacol Exp Ther 213:551-556
11. Chopra S, Kaufman JS, Jones TW, Hong WK, Gehr MK, Hamburger RJ, et al (1982) Cis-diamminedichlorplatinum-induced acute renal failure in the rat. Kidney Int 21:54-64
12. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR (1995) Critical subcellular targets of cisplatin and related platinum analogs in rat renal proximal tubule cells. Kidney Int 48:761-770
13. Townsend DM, Deng M, Zhang L, Lapus MG, Hanigan MH (2003) Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. J Am Soc Nephrol 14:1-10
14. Sternberg CN, Whelan P, Hetherington J, Paluchowska B, Slee PH, Vekemans K, et al (2005) Phase III trial of satraplatin, an oral platinum plus prednisone vs. prednisone alone in patients with hormone-refractory prostate cancer. Oncology 68:2-9
15. Fokkema E, de Vries EG, Meijer S, Groen HJ (2000) Lack of nephrotoxicity of new oral platinum drug JM216 in lung cancer patients. Cancer Chemother Pharmacol 45:89-92
16. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, et al (2005) Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79:451-460
17. Kwon YE, Hwang KJ, Park YJ, Kim KH (2003) Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes. Bioorg Med Chem 11:1669-1676
18. Kwon YE, Kim KH (2006) Octahedral Pt(IV) complex, K101 induces apoptosis via ERK1/2 activation and p53 pathway in human colon cancer cells. Anti-Cancer drugs 17:553-558
19. Gomori G (1956) Histochemical methods for acid phosphatase. Histochem Cytochem 4:453-461
20. Sharratt M, Frazer AC (1963) The sensitivity of function tests in detecting renal damage in the rat. Toxicol Appl Pharmacol 5:36-48
21. Wolfgang GH, Dominick MA, Walsh KM, Hoeschele JD, Pegg DG (1994) Comparative nephrotoxicity of a novel platinum compound, cisplatin, and carboplatin in male Wistar rats. Fundam Appl Toxicol 22:73-79
22. Kersten L, Braunlich H, Keppler BK, Gliesing C, Wendelin M, Westphal J (1998) Comparative nephrotoxicity of some antitumour-active platinum and ruthenium complexes in rats. J Appl Toxicol 18:93-101
23. Uehara T, Watanabe H, Itoh F, Inoue S, Koshida H, Nakamura M, et al (2005) Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats. Arch Toxicol 79:451-460
24. Ward JM, Fauvie KA (1976) The nephrotoxic effects of cis-diammine- dichloroplatinum (II) (NSC-119875) in male F344 rats. Toxicol Appl Pharmacol 38:535-547
25. Ward JM, Young DM, Fauvie KA, Wolpert MK, Davis R, Guarino AM (1976) Comparative nephrotoxicity of platinum cancer chemotherapeutic agents. Cancer Treat Rep 60:1675-1678
26. Esposito M, Viale M, Vannozzi MO, Zicca A, Cadoni A, Merlo F, Gogioso L (1996) Effect of the antiarrhythmic drug procainamide on the toxicity and antitumor activity of cis-diammine-dichloroplatinum(II). Toxicol Appl Pharmacol 140:370-377
27. Sadzuka Y, Shoji T, Takino Y (1991) Change of lipid peroxide levels in rat tissues after cisplatin administration. Toxicol Lett 57:159-166
28. Fenoglio C, Boicelli CA, Ottone M, Addario C, Chiari P, Viale M (2002) Protective effect of procaine hydrochloride on cisplatin-induced alterations in rat kidney. Anticancer Drugs 13:1043-1054